Investigational drug · Phase 2
BMS-986446
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease, Early Onset.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "BMS-986446"
First trial start
2024
Mar 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986446", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease, Early Onset
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986446" as an intervention, largest first.
- Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06268886 · 310 participants (planned) · Start Mar 20, 2024 · Primary completion Dec 17, 2026
Drug: BMS-986446 · For: Alzheimer Disease, Early Onset
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 176 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07780383 · 84 participants (planned) · Start Aug 21, 2026 · Primary completion Jun 17, 2027
Drug: BMS-986446 · For: Alzheimer's Disease; Healthy Participants
Sites: Anaheim, California; Bradenton, Florida; Daytona Beach, Florida · 6 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06955741 · 46 participants · Start May 5, 2025 · Primary completion Sep 11, 2025
Drug: BMS-986446 IV; BMS-986446 SC and 2 more · For: Healthy Volunteer
Sites: Anaheim, California · 2 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06084598 · 24 participants · Start Oct 12, 2023 · Primary completion Mar 8, 2024
Drug: BMS-986446 · For: Healthy Participants
Sites: Cypress, California
- Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.Not yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07852962 · 10 participants (planned) · Start Feb 10, 2027 · Primary completion Jul 18, 2027
Drug: BMS-986446 · For: Healthy Volunteers
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.